MedTrace Logo

Effects of Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury

NCT05398913 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2022-11-15

No results posted yet for this study

Summary

Randomized placebo-controlled safety and feasibility study with crossover design (3 arms). Placebo or Rimonabant 2.5mg or Rimonabant 5mg will be administered for 5 days. Exploratory efficacy will be tested using six-min walking test.

Conditions

  • Spinal Cord Injuries

Interventions

DRUG

Rimonabant

Rimonabant

Sponsors & Collaborators

  • Hospital Nacional de Parapléjicos de Toledo

    lead OTHER

Principal Investigators

  • Antonio Oliviero, MD, PhD · Hospital Nacional de Parapléjicos

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-12
Primary Completion
2022-06-07
Completion
2022-06-07

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05398913 on ClinicalTrials.gov